Liquid Phase Peptide Synthesis Market Analysis

End-User (Pharmaceutical & Biotechnology Industry, Contract Development & Manufacturing organizations, Academic & Research Institutes)

Pharmaceutical & biotechnology industry segment is anticipated to hold 45% share of the global liquid phase peptide synthesis market during the forecast period. This is owing to the extensive use of peptides in drug development and manufacturing. For instance, since 2000, 33 non-insulin peptide medications have received approvals across the globe. Furthermore, these peptide medications are no longer just natural amino acid compositions or hormone mimics. For example, ziconotide14,15 is a neurotoxic peptide derived from the cone snail Conus magus, which was approved in 2004 and is used to manage severe chronic pain; teduglutide is a glucagon-like peptide 2 (GLP-2) analog used to treat short bowel syndrome; and enfuvirtide is a 36-amino acid biomimetic peptide mimicking human immunodeficiency virus (HIV) proteins used in combination therapy for the treatment of HIV-112,13.

Application (Therapeutics, Diagnostics, Research Purposes, cosmetics, Food)

The therapeutics segment in the liquid phase peptide synthesis market is estimated to hold a major revenue share by 2036. due to the increasing demand for peptide-based drugs in various disease treatments. The pharmaceutical industry’s continual efforts to harness peptides for targeted therapies and the development of biologics further bolster this segment’s dominance in the market. According to Research Nester Analysts' analysis, the proportion of cancer patients in the United States who qualify for and benefit from genome-targeted therapy has grown over time, rising from an estimated 2.7 in 2006 to 7% in 2020.

Our in-depth analysis of the global market includes the following segments: